Percutaneous coronary intervention: FAME is lasting

Affiliations

¹ Veterans Affairs New York Harbor Health Care System and New York University School of Medicine, New York, NY 10010, USA. Electronic address: steven.sedlis@med.va.gov.
² Veterans Affairs New York Harbor Health Care System and New York University School of Medicine, New York, NY 10010, USA.

Comment

Steven P Sedlis et al. Lancet. 2015.

. 2015 Nov 7;386(10006):1806-7.

doi: 10.1016/S0140-6736(15)00044-6. Epub 2015 Aug 30.

¹ Veterans Affairs New York Harbor Health Care System and New York University School of Medicine, New York, NY 10010, USA. Electronic address: steven.sedlis@med.va.gov.
² Veterans Affairs New York Harbor Health Care System and New York University School of Medicine, New York, NY 10010, USA.

No abstract available

Comment on

Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial.
van Nunen LX, Zimmermann FM, Tonino PA, Barbato E, Baumbach A, Engstrøm T, Klauss V, MacCarthy PA, Manoharan G, Oldroyd KG, Ver Lee PN, Van't Veer M, Fearon WF, De Bruyne B, Pijls NH; FAME Study Investigators. van Nunen LX, et al. Lancet. 2015 Nov 7;386(10006):1853-60. doi: 10.1016/S0140-6736(15)00057-4. Epub 2015 Aug 30. Lancet. 2015. PMID: 26333474 Clinical Trial.